Since LianBio's initial public listing on Nasdaq in the US, Chinese biotechs continued to attract substantial funding in the last two weeks of November, with mRNA technologies bagging the most attention.
On 29 November, ABOGEN INC announced the completion of a $300m series C+ round on top of the Chinese...